$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents.
Structure Therapeutics (GPCR) Announces Positive Results from Phase 1b Clinical Study of GSBR-1290 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Structure Therapeutics Inc.’s American depositary receipts jumped more than 90% premarket on Friday after the company announced positive results from an.
By Dean Seal Structure Therapeutics' American depositary receipts surged after the company delivered positive results for its weight-loss drug and disclosed.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily.